Please assess the completion status of the following clinical trial:

Trial Title: Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* eligibility to stem cell transplantation~Exclusion Criteria:~* allergy to Zinc~* copper deficiency or Wilson's syndrome~* patients who admit zinc assumption in other drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
- Zinc (Type: EXPERIMENTAL): patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).